Fig. 7: ANXA5 mediates CRK/DOCK180/RAC1 and ERK activities in Hca-P. | Cell Death & Disease

Fig. 7: ANXA5 mediates CRK/DOCK180/RAC1 and ERK activities in Hca-P.

From: Annexin A5 regulates hepatocarcinoma malignancy via CRKI/II-DOCK180-RAC1 integrin and MEK-ERK pathways

Fig. 7

a ANXA5 suppression reduced CRKI, CRKII, DOCK180 and RAC1 in Hca-P. No change was between Hca-P and Hca-P-ANXA5-shControl. Compared with Hca-P-ANXA5-shControl, the different expressions of CRKI, CRKII, DOCK180 and RAC1 in Hca-P-Anxa5-shRNA1 and -shRNA2 were significant (P < 0.05). Decreases in Hca-P-Anxa5-shRNA1 were more clear than Hca-P-Anxa5-shRNA2 cells. b The influence of ANXA5 downregulation on vimentin. c The influence of ANXA5 stable knockdown on critical molecules in ERK pathway. ANXA5 suppression could not alter the levels of MEK, ERK1, and ERK2. Except for p-ERK2 in Hca-P-Anxa5-shRNA2, the decreases of p-MEK (P < 0.01), p-ERK1 (P < 0.01), p-ERK2 (P < 0.001) and C-MYC (P< 0.05) in Hca-P-Anxa5-shRNA1 and -shRNA2 cells were significant than those of Hca-P-Anxa5-shControl, and in Hca-P-Anxa5-shRNA1 were more clear than Hca-P-Anxa5-shRNA2 cells. d ANXA5 knockdown reduces the expression of MMP-9 in Hca-P-Anxa5-shRNA1 (P < 0.001) and -shRNA2 (P < 0.01) cells. Levels are normalized to α-Tubulin. Values mean ± S.D. of three independent experiments

Back to article page